Oral Edaravone Suspension for Stable Drug Concentration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ALS treatments, particularly edaravone injections, impose a significant burden on patients and caregivers, and there is a need for an oral administration form that provides equivalent therapeutic efficacy with reduced variability in drug concentration and improved patient safety, especially for those with dysphagia.
Innovation Solution
A suspension formulation of edaravone particles in water with a dispersant, optionally including a thickening agent, designed to maintain a well-dispersed state and reduce variability in drug concentration, suitable for oral administration, which includes specific particle sizes and concentrations to achieve bioequivalence with intravenous injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If edaravone injection is used for ALS treatment, then therapeutic efficacy is achieved, but patient burden and caregiver burden increase significantly
Solution Approach 1:
The invention changes the administration route from intravenous injection to oral suspension, fundamentally altering the delivery parameters while maintaining therapeutic efficacy. The oral suspension formulation with specific dispersants and viscosity modifiers enables effective drug delivery through the gastrointestinal tract, eliminating the need for invasive injections and reducing patient and caregiver burden.
2Ease of operation
If oral administration form is developed, then patient burden is reduced, but variability in drug concentration increases
Solution Approach 1:
The invention introduces specific dispersants as intermediary substances that mediate between the edaravone particles and the aqueous environment. These dispersants (such as polysorbates, lecithin, or gelatin) prevent particle aggregation and ensure uniform drug distribution throughout the suspension, thereby reducing variability in drug concentration upon administration.
Solution Approach 2:
The invention carefully controls the viscosity parameters of the oral suspension by adding thickening agents like methylcellulose or carboxymethylcellulose. This viscosity control prevents premature sedimentation of edaravone particles while ensuring the suspension remains pourable and administrable, thereby maintaining consistent drug delivery and reducing concentration variability.
3Object-affected harmful factors
If oral suspension is formulated, then aspiration risk is reduced for dysphagia patients, but drug concentration stability decreases
Solution Approach 1:
The invention optimizes the viscosity parameters of the oral suspension to a specific range that balances aspiration prevention with drug stability. The thickening agents increase viscosity sufficiently to prevent aspiration in dysphagia patients while maintaining particle suspension stability through controlled sedimentation rates, thus achieving both safety and compositional stability.
Solution Approach 2:
The invention creates a composite suspension system combining edaravone particles with multiple functional excipients including dispersants (for particle separation), thickening agents (for viscosity control and aspiration prevention), and pH buffers (for stability). This composite formulation achieves both aspiration safety and drug concentration stability through synergistic interactions among components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The suspension formulation allows for stable and effective oral administration, reducing the burden on patients and caregivers, ensuring equivalent therapeutic effects to injections while minimizing variability in drug concentration and reducing the risk of aspiration, particularly for patients with dysphagia.
Implementation Method 1
a dispersant, and water... maintains a well-dispersed state... reducing variability in drug concentration
Data Source
AI summary
An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.